Latest CORENA Manufacturer Release Brings Strong Productivity Improvements
Flatirons Solutions®, part of the Flatirons Jouve™ group of companies, is pleased to announce the latest release of its CORENA Manufacturer solution. CORENA Manufacturer is used to create and revise the technical information needed to maintain and operate complex products, including aircraft, defense equipment, marine vessels and rail assets. This latest release of CORENA Manufacturer features enhancements for both content authors and end-users while building on nearly two decades of continuous research and development.
For authors, the CORENA Knowledge Center content management system at the heart of CORENA Manufacturer receives a major update to its web client user interface, including improvements to support light authoring of S1000D content. CORENA Studio, the CORENA Manufacturer authoring environment, also receives upgrades that include “synchronized rendering” to allow authors to work in structured markup while having an as-needed dynamic view of the styled rendering of the publication. CORENA Studio also features performance improvements to reduce loading times for large documents.
Content end-users also benefit from capabilities delivered as part of this new release. CORENA Pinpoint and CORENA Pinpoint Mobile, the viewers for Interactive Electronic Technical Publications (IETPs), feature support of Airbus A350 technical publications including 3D-enriched manuals. Other updates include enhancements for hyperlink and cross-publication navigation, bookmarking, export and import of annotations, search refinement and search results navigation, and a wealth of other features aimed at making maintenance engineers and operators more productive at the worksite.
“We’re proud of the compelling value that this latest release of CORENA Manufacturer brings to customers, and to our industry. It empowers OEMs to make technical information a product differentiator, not just a cost of doing business,” noted Flatirons CEO JD Sillion. CORENA Manufacturer supports multiple specifications like S1000D, ATA iSpec 2200, and other industry standards. This solution has been adopted by some of the biggest names in aviation and defense, including leading airframe, engine, and component manufacturers. For more details on CORENA Manufacturer, or to request a consultation to understand the full benefits of the solution for your organization, please visit http://bit.ly/2G5Xu5O.
About Flatirons Jouve
Flatirons Jouve (www.flatironsjouve.com) provides solutions and services that organizations need to harness their most complex data, optimize their business processes, and create compelling digital experiences. A longtime leader in content-driven markets like aviation and publishing, Flatirons Jouve™ also provides disruptive innovations to meet knowledge delivery requirements in the manufacturing, banking, insurance, education and public sector.
Flatirons Jouve™ counts 2,500 employees and operates worldwide in 15 countries from offices in North America, Europe, Asia, and Africa.
Flatirons Solutions, Inc.
Patrick Dawson, +1-303-627-6548
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Brightree Acquires Mobile Delivery Provider Apacheta to Streamline HME Delivery17.12.2018 14:05 | Pressemelding
Brightree, a leading provider of cloud-based software helping out-of-hospital providers improve business performance and patient outcomes, today announced it has acquired privately held mobile delivery and cloud-based software-as-a-service (SaaS) provider Apacheta Corporation, further expanding the SaaS portfolio of Brightree’s owner, ResMed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005121/en/ The terms of the transaction were not disclosed. Apacheta offers mobile applications that empower companies to automate and streamline business processes in route sales, field marketing, pick-up and delivery, transportation and field services. Apacheta and its Media, PA-based employees will join Brightree, whose platform it has been integrated with since 2015. A secure mobile delivery module for ordering and tracking medical equipment was the number one feature request of HMEs in a recent customer satisfaction survey. Brigh
Transphorm’s High Voltage GaN FETs Amp Up Marotta Controls’ Military Grade High Frequency Power Supply17.12.2018 14:00 | Pressemelding
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified gallium nitride (GaN) semiconductors—today announced with Marotta Controls that the Aerospace and Defense supplier’s upcoming power supply unit (PSU) replaces incumbent Silicon (Si) MOSFETs with high voltage GaN PQFN devices to offer advanced benefits. Marotta’s latest design operates at high frequency in a conduction-cooled mechanically constrained envelope. The supply’s topology features hard switching and an automatic transformer RESET capability where transistor voltage stresses are clamped to the input voltage. The GaN devices increase the PSU’s efficiency dramatically and alleviate a complex thermal design in the small form factor package. “The demand on our power supplies and expectation of performance is high,” explained Mike Scruggs, Principal Engineer, Marotta Controls. “This particular complex PSU needed to reliably convert and distribute power in a s
New Phase 3 data demonstrate superiority of TREMFYA®▼ (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 4817.12.2018 12:56 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA® (guselkumab) was superior to Cosentyx® (secukinumab)* in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48. Data from the multicentre, randomised, double-blind head-to-head Phase 3 study demonstrated that 84.5 percent of patients treated with guselkumab achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at week 48, compared with 70.0 percent of patients treated with secukinumab (p<0.001).1 These data, presented at the 3rd Inflammatory Skin Disease Summit (ISDS) in Vienna, 12–15 December, mark the first-ever results from a head-to-head study comparing an interleukin (IL)-23-targeted biologic therapy (guselkumab) with an IL-17 inhibitor (secukinumab). ECLIPSE is Janssen’s fourth Phase 3 study for guselkumab in plaque psoriasis2-4 and is part of a comprehen
Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients17.12.2018 12:30 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building in resource-constrained countries around the world. The programs selected are expected to support established institutions partnering with in-country medical centers that provide essential cancer care services including awareness and education, prevention, diagnosis and care. The Celgene Cancer Care Links program is an initiative of Celgene Global Health, which focuses on healthcare challenges facing patients in developing parts of the world. “Celgene Cancer Care Links is another program we have created to make a meaningful impact for patients and healthcare systems around the world,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene. “We are excited to announce the first round of grants through this initiative and wish these world-renowned organizations and institutions
Ras Al Khaimah Marks New Year’s Eve with Amazing Fireworks and New Guinness World Record Bid17.12.2018 11:14 | Pressemelding
This New Year’s Eve, Ras Al Khaimah is the place to be as the Emirate readies to host the most spectacular celebration with a 12-minute fireworks display - the bid for a new Guinness World Record display - and an array of family-oriented activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005309/en/ Marjan, Ras Al Khaimah’s master-developer of freehold projects, will manage the show to mark 2019 with a glittering array of activities that will entertain all at its flagship development, Al Marjan Island. With three additional viewing areas around Al Marjan Island, New Year’s Eve in Ras Al Khaimah has fun and thrills in store for local and international visitors. Abdulla Al Abdouli, Managing Director & CEO of Marjan, said: “This year, we are offering exciting family activities that will delight all in the run-up to the amazing fireworks display that aims to set a new Guinness World Record. The event will position t
Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m Equity Investment17.12.2018 09:52 | Pressemelding
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces that it has entered into a joint venture (‘JV’) agreement with Autobio Diagnostics (‘Autobio’), one of the leading clinical diagnostics companies in China, to commercialise the Novodiag® platform in China. In addition, Mobidiag announces that it has secured a separate €10m equity investment from Autobio. Lynx Financial (HK) Ltd, served as the exclusive financial advisor to Mobidiag in this transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005272/en/ Mobidiag and Autobio will jointly invest €12.3m to establish a joint venture company in China. Autobio will invest €8m in cash to hold 65%, and Mobidiag will invest €4.3m to hold 35%. Mobidiag will grant to the JV an exclusive license for human infectious disease assays (except for sepsis) for China. Initial activities of the JV will i